Odyssey Therapeutics, Inc.
ODTX evidence brief
What we can confirm
- BioSniper Score:
- 9.9 / 10
- Market Cap:
- $1.30B
What it means
What to watch
Prepared research question
What matters most for ODTX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · ODTX
Odyssey Therapeutics (ODTX) is a clinical-stage biopharmaceutical company developing precision medicines for autoimmune and inflammatory diseases, with its lead candidate, OD-001, a first-in-class oral RIPK2 scaffolding inhibitor, having shown positive proof-of-concept in a Phase 2a trial for ulcerative colitis.
Key risk: No revenue, ongoing losses
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Market Cap
$1.30B
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Jun 30, 2026.
Odyssey Therapeutics (ODTX) is a clinical-stage biopharmaceutical company developing precision medicines for autoimmune and inflammatory diseases, with its lead candidate, OD-001, a first-in-class oral RIPK2 scaffolding inhibitor, having shown positive proof-of-concept in a Phase 2a trial for ulcerative colitis.
- Odyssey Therapeutics is a clinical-stage biopharmaceutical company focused on autoimmune and inflammatory diseases [news · published 2026-10-06].
- Lead candidate OD-001 is a first-in-class, oral RIPK2 scaffolding inhibitor that showed positive clinical proof-of-concept in a Phase 2a monotherapy trial for moderate to severe ulcerative colitis [news · published 2026-06-17].
- The company completed an upsized initial public offering in May 2026, pricing 15,500,000 shares at $18.00 per share [news · published 2026-05-08].
- As of June 30, 2026, the company reported cash & equivalents of $82.0M, total revenue of $0.0M, and a net loss of -$52.8M [sec].
- Cash on hand as of March 31, 2026, together with IPO and private placement proceeds of $464M, was expected to fund operations into the second half of 2028 [news · published 2026-06-17].
What works
- Lead candidate OD-001 has achieved positive clinical proof-of-concept in a Phase 2a trial for ulcerative colitis, a significant milestone for a first-in-class drug [news · published 2026-06-17].
- The company has a strong cash position, with $82.0M in cash & equivalents as of June 30, 2026, and prior guidance that combined IPO and private placement proceeds of $464M would fund operations into the second half of 2028 [sec][news · published 2026-06-17].
- Odyssey has attracted positive analyst coverage, with firms like Raymond James and HC Wainwright initiating coverage with Outperform and Buy ratings, respectively [news · published 2026-10-09][news · published 2026-08-27].
What to weigh
- The company has no revenue ($0.0M as of June 30, 2026) and is generating significant net losses ($52.8M net loss for Q2 2026) [sec].
- The company is entirely pre-revenue and dependent on its cash runway to fund operations and clinical trials, with no approved products [sec][news · published 2026-06-17].
- The reported cash figure of $433.1M in a news article from September 14, 2026, appears to conflict with the authoritative SEC figure of $82.0M as of June 30, 2026, raising potential questions about financial reporting consistency [news · published 2026-09-14][sec].
From the filings
Quoted directly from source documents.
Odyssey is a clinical-stage biopharmaceutical company focused on autoimmune and inflammatory diseases.
“Odyssey Therapeutics, Inc. (Nasdaq: ODTX) (“Odyssey” or the “Company”), a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases”
News · October 6, 2026
OD-001 is a first-in-class, oral RIPK2 scaffolding inhibitor with positive Phase 2a proof-of-concept data.
“Reported positive clinical proof-of-concept data for OD-001, our first-in-class, oral RIPK2 scaffolding inhibitor, in a Phase 2a monotherapy trial for moderate to severe ulcerative colitis”
News · June 17, 2026
Cash on hand and IPO proceeds were expected to fund operations into the second half of 2028.
“Cash on hand as of March 31, 2026, together with net proceeds from the IPO, and concurrent private placement, of $464M expected to fund operations into the second half of 2028”
News · June 17, 2026
Risks & what to watch (3)›
Key risks
- No revenue, ongoing losses — Company reported $0.0M revenue and $52.8M net loss for Q2 2026, indicating heavy reliance on funding for operations [sec].
- Cash runway uncertainty — Discrepancy between SEC cash figure ($82.0M as of June 30, 2026) and a news article ($433.1M as of same quarter) creates ambiguity about true financial position [sec][news · published 2026-09-14].
- Single lead candidate risk — Company's prospects hinge on OD-001; any clinical or regulatory setback could severely impact valuation [news · published 2026-06-17].
What to watch
- Upcoming oral presentation of additional Phase 2a induction data for OD-001 in ulcerative colitis at UEG Week 2026 on October 20, 2026 [news · published 2026-10-06].
- Clarity on cash position and burn rate in subsequent quarterly financial reports, given the discrepancy between SEC and news-reported figures [sec][news · published 2026-09-14].
- Any updates on pipeline expansion or new clinical trial initiations beyond OD-001 [news · published 2026-06-17].
- Analyst coverage and potential partnership or licensing deals that could provide non-dilutive funding [news · published 2026-10-09][news · published 2026-08-27].
Sources: News · Generated October 13, 2026 · How we verify sources →
Run Odyssey Therapeutics, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Odyssey Therapeutics, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 2 of 6 signals · derived from public data
Pipeline inputs are unavailable for this score. It uses only the available signals shown below.
Cash runway data unavailable
D/E 0.15 · 0% dilution
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
9 buys · 3 sells (180d)
Financials
Frequently asked questions
What is the AI investment thesis for Odyssey Therapeutics, Inc.?
Odyssey Therapeutics (ODTX) is a clinical-stage biopharmaceutical company developing precision medicines for autoimmune and inflammatory diseases, with its lead candidate, OD-001, a first-in-class oral RIPK2 scaffolding inhibitor, having shown positive proof-of-concept in a Phase 2a trial for ulcerative colitis.
Who is the CEO of Odyssey Therapeutics, Inc.?
Dr. Gary D. Glick Ph.D. is the chief executive officer of Odyssey Therapeutics, Inc. (ODTX).
Where is Odyssey Therapeutics, Inc. headquartered?
Odyssey Therapeutics, Inc. (ODTX) is headquartered in Boston, MA, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.